HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Helbig, G. Articles by Holowiecki, J. Search for Related Content PubMed PubMed Citation Articles by Helbig, G. Articles by Holowiecki, J.

Interferon induces a good molecular response in a patient with chronic eosinophilic leukemia (CEL) carrying the JAK2V617F point mutation

¹ Departament of Haematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, Poland;
² Institute of Hematology and Transfusion Medicine, Warsaw, Poland

Correspondence: Grzegorz Helbig, MD. Departament of Haematology and Bone Marrow Transplantation, Silesian Medical University, 40-027 Katowice, Dabrowski str. 25, Poland Tel: +48.322591236, Fax: +48.322554985. E-mail: ghelbig{at}o2.pl

The JAK2 V617F point mutation is very rare in hypereosinophilic syndome and/or chronic eosinophilic leukemia. Here we report on a patient with chronic eosinophilic leukemia and detectable JAK2 mutant clone, who achieved a good molecular response to interferon -2a after 4 months of treatment. The molecular response correlated with only moderate haematological improvement

Key words: JAK2 V617F mutation, interferon , hypereosinophilic syndrome, chronic eosinophilic leukemia, molecular response.